Black Diamond Therapeutics, Inc. (BDTX)
Largest Insider Buys in Sector
BDTX Stock Price History Chart
BDTX Stock Performance
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance …
Insider Activity of Black Diamond Therapeutics, Inc.
Over the last 12 months, insiders at Black Diamond Therapeutics, Inc. have bought $0 and sold $1.4M worth of Black Diamond Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Black Diamond Therapeutics, Inc. have bought $60M and sold $10.24M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 400,000 shares for transaction amount of $934,080 was made by BIOTECH GROWTH N V (10 percent owner) on 2023‑10‑17.
List of Insider Buy and Sell Transactions, Black Diamond Therapeutics, Inc.
| 2024-08-28 | Sale | 10 percent owner | 221,600 0.3894% | $6.32 | $1.4M | -35.95% | ||
| 2023-10-17 | 10 percent owner | 400,000 0.7707% | $2.34 | $934,080 | +99.57% | |||
| 2023-07-05 | director | 1M 2.8199% | $5.00 | $5M | -26.34% | |||
| 2023-07-05 | director | 935,850 2.639% | $5.00 | $4.68M | -26.34% | |||
| 2023-06-30 | 10 percent owner | 1M 2.7138% | $5.00 | $5M | -28.71% | |||
| 2023-06-27 | Sale | SEE REMARKS | 25,000 0.0743% | $6.70 | $167,500 | -41.59% | ||
| 2023-06-27 | 10 percent owner | 1.74M 4.2378% | $5.49 | $9.56M | -41.59% | |||
| 2022-12-22 | SEE REMARKS | 36,363 0.0972% | $1.28 | $46,596 | +73.11% | |||
| 2022-12-21 | SEE REMARKS | 20,000 0.0546% | $1.29 | $25,770 | +74.62% | |||
| 2022-10-31 | director | 99,801 0.268% | $2.25 | $224,912 | -6.28% | |||
| 2022-10-28 | director | 172,974 0.4696% | $2.18 | $376,962 | -1.81% | |||
| 2022-10-27 | director | 191,678 0.5124% | $1.87 | $359,224 | +12.69% | |||
| 2022-10-21 | director | 87,850 0.2313% | $1.51 | $132,750 | +37.97% | |||
| 2022-10-20 | director | 53,734 0.144% | $1.42 | $76,345 | +48.97% | |||
| 2022-10-19 | director | 77,689 0.2096% | $1.32 | $102,775 | +61.48% | |||
| 2022-06-29 | SEE REMARKS | 25,000 0.0681% | $2.44 | $61,018 | -16.60% | |||
| 2022-04-27 | 150,000 0.4047% | $2.66 | $399,480 | -22.79% | ||||
| 2022-04-18 | 150,000 0.4099% | $3.29 | $493,935 | -35.24% | ||||
| 2022-04-12 | 150,000 0.4078% | $3.42 | $513,600 | -37.46% | ||||
| 2021-05-12 | Sale | See Remarks | 4,078 0.0111% | $27.42 | $111,805 | -72.50% |
Insider Historical Profitability
| Versant Venture Capital VI, L.P. | 10 percent owner | 3726341 6.5947% | $3.29 | 1 | 28 | <0.0001% |
| BIOTECH GROWTH N V | 10 percent owner | 8517839 15.0745% | $3.29 | 9 | 0 | +10.34% |
| Behbahani Ali | director | 4448757 7.8732% | $3.29 | 2 | 0 | <0.0001% |
| BB BIOTECH AG | 4438402 7.8549% | $3.29 | 3 | 0 | <0.0001% | |
| RA CAPITAL MANAGEMENT, L.P. | director | 3213828 5.6877% | $3.29 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Bellevue Group | $43.19M | 15.14 | 8.52M | -0.21% | -$91,260.00 | 0.66 | |
| T Rowe Price Investment Management Inc | $34.1M | 11.96 | 6.73M | +71.22% | +$14.18M | 0.02 | |
| Nea Management Company Llc | $22.56M | 7.91 | 4.45M | 0% | +$0 | 0.11 | |
| RA Capital Management, L.P. | $17.88M | 6.27 | 3.53M | 0% | +$0 | 0.02 | |
| The Vanguard Group | $9.66M | 3.39 | 1.91M | -2.15% | -$211,890.51 | <0.0001 |